Trubion Pharmaceuticals Provides Announcement Dates for First-Quarter Earnings Conference Call

Friday, May 2, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SEATTLE, May 1 Trubion Pharmaceuticals, Inc.(Nasdaq: TRBN), today announced it plans to issue earnings results for thefirst quarter ended March 31, 2008, after the close of market on May 8, 2008.The company's earnings conference call will take place May 8, 2008, at 2 p.m.PDT (5 p.m. EDT).

Both live events will be available for viewing on Trubion's website athttp://investors.trubion.com/events.cfm.

First-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, May 8,2008

Participants are invited to call 1(877) 545-1488 or 1 (719) 325-4899. Areplay of the discussion will be available after 5 p.m. PDT / 8 p.m. EDT byvisiting Trubion's website or by calling 1(888) 203-1112 or 1 (719) 457-0820,and entering 7602146. The replay will be available until midnight, Monday,May 12.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline ofnovel protein therapeutic product candidates to treat autoimmune andinflammatory diseases and cancer. The company's mission is to develop avariety of first-in-class and best-in-class product candidates, customized foroptimal safety, efficacy, and convenience that it believes may offer improvedpatient experiences. Trubion's current product candidates are novelsingle-chain protein, or SMIP(TM), therapeutics, and are designed using itscustom drug assembly technology. Trubion's product pipeline includesCD20-directed candidates such as TRU-015 and SBI-087 for autoimmune andinflammatory diseases, developed under the company's Wyeth collaboration.Trubion's proprietary product candidate, TRU-016, is a novel CD37-targetedtherapy for the treatment of B-cell malignancies currently in Phase 1/2clinical evaluation. In addition to Trubion's current product candidates, thecompany is also developing additional alliance and proprietary productcandidates that build on its product development experience. More informationis available in the investors section of Trubion's website:investors.trubion.com.Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. (206) 838-0500 jdenike@trubion.com http://www.trubion.comTRBN-G

SOURCE Trubion Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook